August 13, 2019 by Steve Blade
The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of
Growth of the global movement disorders market is projected to be bound by various macro-economic and micro-economic factors. Lack of ability to move due to growing prevalence of factors such as cerebrovascular diseases, trauma, brain tumors, degenerative diseases and convulsive diseases continues to impact the global market growth of movement disorder positively. Prevalence of neurological disorders negatively affect the cognitive abilities and lead to depression, incapability to chew, swallowing, speaking and insomnia. Growing awareness regarding the prevalence of various mental diseases will further contribute towards the global market growth of movement disorder significantly.
For More Details - A sample of this report is available upon request here -
Prevalence of the mental disorders has continued to remain high among the old aged population globally. Neurological diseases such as Huntington’s disease, Parkinson’s disease and multiple symptom atrophy (MSA) continues to propel demand for management of the movement disorders. Lack of production of brain chemical dopamine by the nerve cells in the brain leads to uncoordinated movements and mental disorders that impact the everyday activities of the persons.
Parkinson ’s disease to Represent a Leading Segment
Growing need for medical devices with the uninterrupted functioning for treatment of the neurological disorders has led to an upsurge in adoption of rechargeable deep brain stimulator devices. On the basis of product type, the rechargeable deep brain stimulator devices segment is expected to generate significant revenues, accounting for a value of over US$ 500 Mn by the end of 2026. However, the non-rechargeable deep brain stimulator devices product type segment is expected to register the highest CAGR during the forecast period.
Based on end user, the hospitals segment is expected to represent the highest revenue growth, recording a value of less than US$ 100 Mn by the end of 2017. On the other hand, the clinics end user segment is expected to register a robust through 2026.
By application, the Parkinson’s disease segment is expected to represent a significant revenue growth, accounting for a value of over US$ 400 Mn by the end of 2026. In contrary to this, the dystonia application segment is expected to register a healthy CAGR throughout the forecast period.
Leading market players operating in the global movement disorder market include Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation and Mayo Clinic.
Have Any Query?? Ask Our Industry Expert
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852